| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
GRH-SOMATOSTATIN-GH |
Department of Internal Medicine (C.M.S., M.T.K., K.K.L.), Division of Endocrinology, University of Virginia, Charlottesville, Virginia 22908; Endocrine Sciences Research Group (A.J.W., J.S.F., T.H., A.J.W., P.E.C.) and Department of Surgery (N.A.), University of Manchester, Manchester, M13 9PT United Kingdom (N.A.)
Address all correspondence and requests for reprints to: Corinne M. Silva, Box 800746, University of Virginia Health System, Charlottesville, Virginia 22908. E-mail: . cms3e{at}virginia.edu
We have investigated and compared GH and epidermal growth factor (EGF) signaling in primary human skin fibroblasts from normal subjects and subjects with GH-binding protein-positive Laron syndrome (LS). In normal human fibroblasts, GH and EGF activate the tyrosine phosphorylation of signal transducer and activator of transcription (STAT)1 and STAT5b; in LS fibroblasts, EGF does, but GH does not. GH also activates the tyrosine phosphorylation of Janus kinase (JAK)2 in normal, but not LS, fibroblasts. Similarly, both GH and EGF activate MAPK in normal fibroblasts, but only EGF does in the LS fibroblasts. As in the 3T3-F442A mouse preadipocyte cell line, GH signaling to mitogen-activated protein kinase is partially inhibited by wortmannin treatment, indicating a role for phosphatidylinositol 3-kinase (PI3K) in this signaling pathway. The exogenous expression of the GH receptor in one family of LS fibroblasts (H1) but not the other (M) restores signaling to a STAT5 reporter element. Together, these results indicate that the mechanism of defective GH signaling in two families of LS fibroblasts are different but that both occur at a level close to, and specific for, the GH receptor.
This article has been cited by other articles:
![]() |
M. O Savage, C. Camacho-Hubner, A. David, L. A Metherell, V. Hwa, R. G Rosenfeld, and A. J L Clark Idiopathic short stature: will genetics influence the choice between GH and IGF-I therapy? Eur. J. Endocrinol., August 1, 2007; 157(suppl_1): S33 - S37. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. O. L. Jorgensen, N. Jessen, S. B. Pedersen, E. Vestergaard, L. Gormsen, S. A. Lund, and N. Billestrup GH receptor signaling in skeletal muscle and adipose tissue in human subjects following exposure to an intravenous GH bolus Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E899 - E905. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Goldshmit, C. E. Walters, H. J. Scott, C. J. Greenhalgh, and A. M. Turnley SOCS2 Induces Neurite Outgrowth by Regulation of Epidermal Growth Factor Receptor Activation J. Biol. Chem., April 16, 2004; 279(16): 16349 - 16355. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Hwa, B. Little, E. M. Kofoed, and R. G. Rosenfeld Transcriptional Regulation of Insulin-like Growth Factor-I by Interferon-{gamma} Requires STAT-5b J. Biol. Chem., January 23, 2004; 279(4): 2728 - 2736. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Kofoed, V. Hwa, B. Little, K. A. Woods, C. K. Buckway, J. Tsubaki, K. L. Pratt, L. Bezrodnik, H. Jasper, A. Tepper, et al. Growth Hormone Insensitivity Associated with a STAT5b Mutation N. Engl. J. Med., September 18, 2003; 349(12): 1139 - 1147. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |